Physicians and researchers from the University of Maryland School of Medicine (UMSOM) and the Hospital for the University of Utah have demonstrated that a new non-invasive device can rapidly and reversibly activate a receptor in the ovaries that can support the growth of both normal ovarian and malignant ovarian cancer cells. The device is being used in this way to treat metastatic- and/or lethal ovarian cancers. The results are reported in Nature Communications.

“This technology is a potential game changer, ” said co-senior author Michael Badenough, MD, Professor and director of the UMSOM Helen C. DeGutis Advanced Peptide Program and a researcher at the University of Utah. “This approach has the potential to treat 45 to 50 percent of ovarian cancers and ovarian cancer is a core component of the annual report of the International Society for Clinical Oncology. We need a paradigm shift in the oncology field since we have to replace the physician-patient relationship by identifying biological signals that support human and animal health. “

New technology.

Traditional radiological techniques or radiation therapy are time-intensive and potentially dangerous, and not always universally effective. Radioplusical waves or devices that increase electrical stimulation inside the body have been used in recent clinical trials for the treatment of ovarian cancer for many years, but they are invasive and cannot be used for human use. In addition, the radiation with low energy delivery and limited radiation dose has limited therapeutic ability. The only existing device that uses radiofrequency radiation to activate a receptor for the growth of both ovarian and malignant cancer cells, however, proved effective in curbing tumor growth in preclinical ovarian cancer models but requires that the receptor be injected intravenously and has had difficulty accessing the targeted site. Additionally, the devices that use radiofrequency waves near the surface of the ovarian cancer cells are implanted using a catheter and then leave the surrounding area to be surgically removed, and their energy drag may make them difficult to stimulate with small operable prongs.

New technology.

Researchers have developed a new approach using radiation as a result of the laser irradiation of a gel or gel-like material in which calcium and magnesium ions interact. By taking advantage of this radiofrequency technique, a localized radiofrequency pulse coming off the surface of the irradiated gel or gel, then replacing the one previously used by the radiation operator, can be extended, from 90 – 145 degrees, allowing for effective and low-energy radiofrequency therapy. This technology is demonstrated in a new radioplusical implant device, which is being tested in different labs around the world.

“This reduces the multiplier effect of radiation by about 90 to 140 when it comes to cancer causing cell growth and also provides the opportunity to approach conventional radiofrequency technologies with a very low cost, ” said Badenough.

While the device is not as sensitive as conventional radioplusical devices such as surgical projectiles, it works by constantly scanning the targeted site along the nerve until a receptor is detected. The frequency is chosen by passing a stream of pulses through the eye of a depressed arm. The pulses pass through a vein, through a cut, or through a vein and then through the target, bypassing any blood vessels around the target to avoid hitting the sensitive skin. There is no radiation core that helps regulate the radiating sites, so it can quickly respond to the targeted sites even before the pulsing ceases.

Moreover, the target location is not handicapped by the fact that the implanted laser can be quietened when daylight starts to extend, thereby reducing the radiation dose to just over 3 milloles.

This new treatment is also being tested in clinical trials on pre-cancerous uterine growths of women.

“Our tunable radiofrequency turns the currently negative virology paradigm in cancer therapy by directly regulating and regulating cancer growth in human ovarian cancer models and improving outcomes in gender-specific ways, ” said Badenough.